Bryan P. Schneider, MD
2013-2014 BCRF Project:
(The J.C. Penney Award)
Associate Professor, Department of Medical and Molecular Genetics
Associate Professor, Department of Medicine
Associate Director, Indiana Institute for Personalized Medicine
Melvin and Bren Simon Cancer Center
Indiana University School of Medicine
(Conquer Cancer Foundation of ASCO 2011 Advanced Clinical Research Award)
Antibodies Neuropathy, one of the most common toxicities associated with taxane therapy (e.g. paclitaxel, docetaxel), may be severe, function-limiting, and sometimes irreversible. Established predictors for increased risk include advanced age, diabetes, and type/dose/schedule of taxane. No established biomarkers have been identified to predict patients who are at greatest risk. Dr. Schneider’s work builds on several relevant multi-institutional clinical trials that have been performed through the Eastern Cooperative Oncology Group (ECOG).
Continuing to collaborate with fellow BCRF grantee, Dr. George Sledge, Jr., formerly at Indiana University and now at Stanford University, Dr. Schneider plans to validate findings from the E1199 clinical trial, which was a pivotal phase III trial that directed the optimal schedule/type of taxane to be used in the adjuvant setting for breast cancer. In that trial, weekly paclitaxel was found to have superior survival when compared with the control arm of paclitaxel every three weeks. Unfortunately, this drug/schedule had the highest risk of neuropathy as well. Dr. Schneider hopes to determine the threshold of discrimination necessary for a predictive genomic biomarker to be clinically relevant. He will formally assess what incremental increase in toxicity is necessary for a patient to alter a therapeutic decision. In summary, he plans to validate the findings in E1199 and create a clinically relevant genetic signature to best counsel patients on the individualized efficacy: toxicity ratio for the taxanes.
Dr. Schneider is an Associate Director of the Indiana Institute for Personalized Medicine and an Assistant Professor of Medicine at the Indiana University Melvin and Bren Simon Cancer Center. He holds appointments in the Divisions of Hematology/Oncology and Clinical Pharmacology in the Department of Medicine with a secondary appointment in the Department of Medical and Molecular Genetics. Dr. Schneider completed his Medical School, Internal Medicine Residency and Hematology/Oncology Fellowship at Indiana University.
Dr. Schneider devotes his clinical time caring for breast cancer patients as a medical oncologist and has a special interest in novel therapeutic agents. He is the model example of a translational scientist, as his laboratory work is both an extension of and complementary to his clinical interesst. His laboratory focus is on pharmacogenetics of breast cancer therapeutics. His biomarker work to date has opened the door for the potential enrichment of patient selection for bevacizumab (Avastin®).
Based on his early work, Dr. Schneider has designed correlative trials in collaborations with multiple groups to better guide proper patient selection for these agents. He is extensively published in the area of therapeutic individualization (i.e. "finding the right drug for each patient.") He is a recipient of the Komen Promise Award and a member of the Komen Scientific Advisory Council. Dr. Schneider is the Chair of the Educational Symposium for the Developmental Therapeutics Committee, the Vice-Chair of the Pharmacogenetics Committee, and a member of the Breast Cancer Committee for the Eastern Cooperative Oncology Group (ECOG). He is also a member of the Consortium on Breast Cancer Pharmacogenetics (CoBRA) and the Pharmacogenetics Research Network (PGRN).